MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE

1 . A pharmaceutical composition comprising:

(a) an immediate release component, wherein the immediate release component comprises 4-((L-valyl)oxy)butanoic acid; and

(b) a modified release component, wherein

the modified release component comprises modified release granules; and

the modified release component comprises 4-((L-valyl)oxy)butanoic acid;

wherein a weight ratio of 4-((L-valyl)oxy)butanoic acid in the immediate release component to 4-((L-valyl)oxy)butanoic acid in the modified release component is from 1:1 to 1:4.

2 . The pharmaceutical composition of claim 1 , wherein,

the immediate release component comprises from 10 wt % to 50 wt % of 4-((L-valyl)oxy)butanoic acid; the modified release component comprises from 50 wt % to 90 wt % of 4-((L-valyl)oxy)butanoic acid; and

wt % is based on the total weight of 4-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.

3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises from 0.1 g to 20 g of 4-((L-valyl)oxy)butanoic acid.

4 . The pharmaceutical composition of claim 1 , wherein

the immediate release component comprises from 2 g to 4 g of 4-((L-valyl)oxy)butanoic acid; and

the modified release component comprises from 8 g to 16 g of 4-((L-valyl)oxy)butanoic acid.

5 . The pharmaceutical composition of claim 1 , wherein the immediate release component comprises immediate release granules comprising 4-((L-valyl)oxy)butanoic acid.

6 . The pharmaceutical composition of claim 5 , wherein the immediate release granules have an average diameter from 75 μm to 450 μm, wherein the average diameter is determined by sieve analysis or by laser diffraction.

7 . The pharmaceutical composition of claim 5 , wherein

the immediate release granules comprise greater than 80 wt % of 4-((L-valyl)oxy)butanoic acid; and

wt % is based on the total weight of the immediate release granules.

8 . The pharmaceutical composition of claim 5 , wherein the immediate release granules comprise hydroxypropylmethyl cellulose and talc.

9 . The pharmaceutical composition of claim 1 , wherein the modified release granules have an average diameter from 150 μm to 400 μm, wherein the average diameter is determined by sieve analysis or by laser diffraction.

10 . The pharmaceutical composition of claim 1 , wherein

the modified release granules comprise a core and a modified release coating surrounding the core;

the core comprises greater than 80 wt % of 4-((L-valyl)oxy)butanoic acid; and

wt % is based on the total weight of the core.

11 . The pharmaceutical composition of claim 1 , wherein

the modified release granules comprise greater than 60 wt % of 4-((L-valyl)oxy)butanoic acid; and

wt % is based on the total weight of the modified release granules.

12 . The pharmaceutical composition of claim 1 , wherein the modified release granules comprise dibutyl sebacate and talc.

13 . The pharmaceutical composition of claim 1 , wherein the immediate release component comprises 4-((L-valyl)oxy)butanoic acid dissolved in a solution.

14 . The pharmaceutical composition of claim 1 , wherein

the pharmaceutical composition comprises a suspension; and

the modified release component comprises the modified release granules dispersed in the suspension.

15 . A kit comprising the pharmaceutical composition of claim 1 .

16 . A method of treating a disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1 , wherein the disease is selected from narcolepsy, excessive daytime sleepiness, cataplexy, excessive daytime sleepiness associated with narcolepsy, excessive daytime sleepiness associated with Parkinson's disease, excessive daytime sleepiness associated with multiple sclerosis, cataplexy associated with narcolepsy, fatigue, fatigue associated with Parkinson's diseases, fatigue associated with multiple sclerosis, and fibromyalgia.

17 . A method of treating a disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1 , wherein the disease is selected from rapid eye movement sleep behavior disorder, spasmodic dystonia, symptoms of schizophrenia, insomnia, insomnia associated with schizophrenia, idiopathic hypersomnia, chronic fatigue syndrome, cluster headache, symptoms of Alzheimer's disease, symptoms of Parkinson's disease, essential tremor, posttraumatic stress syndrome, insomnia associated with posttraumatic stress syndrome, and anxiety.

18 . The method of claim 16 , wherein administering comprises administering a once a day dosing composition.

19 . The method of claim 16 , wherein administering comprises administering a twice a day dosing composition.